<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0" xmlns:cc="http://cyber.law.harvard.edu/rss/creativeCommonsRssModule.html">
    <channel>
        <title><![CDATA[Stories by Quoc-Dien Trinh on Medium]]></title>
        <description><![CDATA[Stories by Quoc-Dien Trinh on Medium]]></description>
        <link>https://medium.com/@prorenata?source=rss-dfa0c514e8a6------2</link>
        <image>
            <url>https://cdn-images-1.medium.com/fit/c/150/150/1*nxZduFYPeoDGBTKRvLQrBw.jpeg</url>
            <title>Stories by Quoc-Dien Trinh on Medium</title>
            <link>https://medium.com/@prorenata?source=rss-dfa0c514e8a6------2</link>
        </image>
        <generator>Medium</generator>
        <lastBuildDate>Sat, 21 Nov 2026 20:44:32 GMT</lastBuildDate>
        <atom:link href="https://medium.com/@prorenata/feed" rel="self" type="application/rss+xml"/>
        <webMaster><![CDATA[yourfriends@medium.com]]></webMaster>
        <atom:link href="http://medium.superfeedr.com/" rel="hub"/>
        <item>
            <title><![CDATA[Does race matter in active surveillance for prostate cancer?]]></title>
            <link>https://medium.com/@prorenata/https-medium-com-prorenata-does-race-matter-in-active-surveillance-for-prostate-cancer-a6b18a5c7188?source=rss-dfa0c514e8a6------2</link>
            <guid isPermaLink="false">https://medium.com/p/a6b18a5c7188</guid>
            <category><![CDATA[culture]]></category>
            <category><![CDATA[race]]></category>
            <category><![CDATA[mens-health]]></category>
            <category><![CDATA[health]]></category>
            <category><![CDATA[cancer]]></category>
            <dc:creator><![CDATA[Quoc-Dien Trinh]]></dc:creator>
            <pubDate>Tue, 18 Jun 2019 14:55:27 GMT</pubDate>
            <atom:updated>2019-06-18T14:55:27.892Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*a9m3C_Qs5JEvaI8sP1i-Zw.jpeg" /><figcaption>Photo by <a href="https://unsplash.com/@matheusferrero?utm_source=unsplash&amp;utm_medium=referral&amp;utm_content=creditCopyText">Matheus Ferrero</a></figcaption></figure><p>According to the <a href="https://www.cancer.org/cancer/prostate-cancer/about/key-statistics.html">American Cancer Society</a>, prostate cancer is the second most common cancer in American men, trailing only skin cancer. In 2019, there will be an estimated 174,650 new cases of prostate cancer and 31,620 of those unfortunate cases will result in death.</p><blockquote>One in nine men will be diagnosed with prostate cancer — the odds increase progressively with age. For a cancer so prevalent, the way it is treated should be as calculated and as accurate as possible. For a while, though, it wasn’t. And in some ways, it’s still not.</blockquote><p>For years, the procedure for men with low-risk prostate cancer has been pitifully one-dimensional. For the most part, there were two options to choose from: you could either opt for radical prostatectomy — a procedure in which the prostate gland is removed, and several lifestyle changes are necessitated; or, you could choose radiation therapy — during which internal or external beams of radiation work to weaken the cancer and prevent its spread.</p><p>These options seem a bit drastic for a low-risk cancer, don’t they?</p><blockquote>With recent evidence, a third option has emerged — one that most specialists could get behind: <strong><em>active surveillance</em></strong>, <a href="https://www.cancer.gov/publications/dictionaries/cancer-terms/def/active-surveillance">officially defined</a> as “a treatment plan that involves closely watching a patient’s condition but not giving any treatment unless there are changes in test results that show the condition is getting worse.”</blockquote><p>Physicians have begun to use this method more frequently in the past decade, and while steps are certainly being taken in the right direction, a <a href="https://www.nejm.org/doi/full/10.1056/NEJMc1900333">recent study</a> conducted by members of the Dana-Farber Cancer Institute and Brigham Health in Boston, MA, revealed a disparity that exists not in <em>how many </em>receive active surveillance, but in <em>who.</em></p><p>In a fascinating brief report, Dr. Brandon Mahal, MD, and colleagues found promising trends in the use of active surveillance: increased implementation in the first half of the decade — from approximately 15% of patients diagnosed with low-risk prostate cancer to around 40%. Despite this increase, the report found that <strong>nonblack patients are still more likely to receive active surveillance than black patients.</strong></p><p>Could the cause of this be biological differences in the cancers of black and nonblack men, keeping with the long-standing thought that black and nonblack patients <em>do</em>differ in biology?</p><p>The simple answer: No.</p><p><a href="https://twitter.com/beam_doc?lang=en">Mahal</a> explains:</p><blockquote>“In this study of over 50,000 men with low risk prostate cancer, including over 7,000 black men, we found that rates of active surveillance nearly tripled regardless of race; however, overall rates of active surveillance for black men were lower than non-black men. Notably, we found that socioeconomic status accounted for a significant proportion of racial differences in AS. Furthermore, the overall uptake of AS from 2010–2015 was lower for black compared to non-black men, even after accounting for socioeconomic differences.”</blockquote><p>Of the 50,203 eligible patients, 7,517 (14.9%) were black and 42,785 (85.1%) were not. Between 2010 and 2015, the use of radical prostatectomy decreased from 48.8% to 41.4% in nonblack patients. Similarly, the use of definitive radiotherapy decreased from 46.0% to 34.8% in these same patients.</p><p>The numbers for black patients follow this trend as well; use of radical prostatectomy fell from 48.5% to 31.8% and use of radiation fell from 36.7% to 24.9%. During this same period, a massive increase in the use of active surveillance took place, with a 14.8% usage rate skyrocketing to 43.3% in nonblack patients and a 12.6% usage rate increasing to 36.4% in black patients.</p><p>This is great, but why the difference between black and nonblack patients?</p><p>According to co-author Dr. <a href="https://twitter.com/qdtrinh?lang=en">Quoc-Dien Trinh</a>, MD, the reasons are still up for debate:</p><blockquote>“Our study found that Black men are receiving active surveillance at a lower rate than nonblack men. It’s possible that Black men are more inclined to proceed with definitive therapy, for whatever reason. On the other end, it’s also possible that physicians are less inclined to offer surveillance to Black men, given the data suggesting worse outcomes on surveillance for Black men.”</blockquote><p>There are several possibilities for this oddity, but when adjusted for socio-economic status or insurance status, the aforementioned disparity of <em>who </em>is revealed. Upon adjustment for these factors, the disparity disappears, meaning that <strong>black men have a lower chance of receiving active surveillance than nonblack men due to socioeconomic or insurance status</strong>.</p><p>Now, there is certainly more information to be found. Tremendous progress has been made towards inclusivity and racial equality in the last few years, perhaps more so than any other period in history. So, it will soon be necessary — when the data becomes available — to review the second half of this decade.</p><blockquote>Problems in equal and equitable care lie beneath the surface in practically every corner of the healthcare industry. Especially pertaining to prostate cancer, a cancer that is particularly troublesome among blacks compared to other cancers, it is absolutely necessary to take a look in the proverbial mirror and understand what causes these problems.</blockquote><p>Is the system skewed? Are we not doing our jobs properly?</p><p>Even worse, do we think we’re doing our jobs properly, while inherent biases fester within us, without our knowledge?</p><p>These are difficult questions that will require strong-willed people to provide uncomfortable answers, but until resolved, the lives of thousands of men, born into conditions they have no control over, may continue to be a collateral of an unjust healthcare system.</p><p><a href="https://medium.com/u/98a896759b55"><em>Andrew Cataldo</em></a><em> is a Spring 2019 Urology Writing Fellow.</em></p><p>Story editor: <a href="https://medium.com/u/b297570deda7">Junaid Nabi</a></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=a6b18a5c7188" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Can equal access overcome race‐based differences in survival for cancer patients?]]></title>
            <link>https://medium.com/pro-re-nata/can-equal-access-overcome-race-based-differences-in-survival-for-cancer-patients-69d9da3506c2?source=rss-dfa0c514e8a6------2</link>
            <guid isPermaLink="false">https://medium.com/p/69d9da3506c2</guid>
            <category><![CDATA[health]]></category>
            <category><![CDATA[cancer]]></category>
            <category><![CDATA[race]]></category>
            <category><![CDATA[healthcare]]></category>
            <category><![CDATA[equality]]></category>
            <dc:creator><![CDATA[Quoc-Dien Trinh]]></dc:creator>
            <pubDate>Mon, 20 May 2019 20:08:35 GMT</pubDate>
            <atom:updated>2019-05-20T20:08:35.128Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*oxwoWte9Sx6pCxC04PcilA.jpeg" /><figcaption>Photo by <a href="https://unsplash.com/photos/05kHY7AYCp8?utm_source=unsplash&amp;utm_medium=referral&amp;utm_content=creditCopyText">Richard Catabay</a> on <a href="https://unsplash.com/search/photos/surgery?utm_source=unsplash&amp;utm_medium=referral&amp;utm_content=creditCopyText">Unsplash</a></figcaption></figure><p>By <a href="https://medium.com/u/98a896759b55">Andrew Cataldo</a></p><p>We have long known that minorities with cancer have worse outcomes compared to non-Hispanic Whites. The reason for these differences is not well understood. While some attribute this phenomenon to differences in behavioral risk factors like smoking, or differences in tumor biology, many researchers have highlighted the role of differences in health care delivery and access to care.</p><p>Although the presence of unequal health outcomes does not automatically mean that there is unfairness in health care delivery, recent evidence suggests that this may be the case.</p><p>While US society struggles with remnants of its unequal nature, the push to make healthcare delivery more equal has accelerated in recent years. Now, a <a href="https://onlinelibrary.wiley.com/doi/abs/10.1002/cncr.31926">recent study</a> conducted by members of the Brigham and Women’s Hospital’s Division of Urology may have provided insights on why these differences may occur.</p><p>According to the <a href="https://www.cancer.org/cancer/bladder-cancer/about/key-statistics.html">American Cancer Society</a>, bladder cancer is one of the most common cancers in the US — with nearly 80,500 American adults affected by it every year. It typically affects adults, specifically those over the age of 60 and begins in the cells that line the inside of the bladder. Though it affects people of all ages and genders, this cancer is typically found in older men.</p><h4>As is the case in other cancers, Black men and women with bladder cancer do much worse than non-Hispanic Whites.</h4><p>While addressing racial differences in outcomes is challenging, understanding why these disparities occur can help to address it. Using a national sample of bladder cancer patients, researchers investigated whether these differences in bladder cancer survival rates could simply be explained by biological differences in tumor characteristics, or if a much larger problem was at play.</p><p>To understand the reason for the disparity in survival rates between White and minority patients, data was extracted from the National Cancer Data Base (NCDB) on Black and White adults with muscle-invasive bladder cancer from 2004 to 2015. Using a statistical model that adjusted for demographic and health status differences, the survival rate for each ethnicity was calculated.</p><p>This investigation <a href="https://onlinelibrary.wiley.com/doi/abs/10.1002/cncr.31926">revealed</a> that black patients had an 18% worse mortality rate than their white counterparts. Overall, race is challenging to study. Unlike studying a new drug, patients cannot be “randomized” to one race or another, nor can patients easily be randomized to insured versus un-uninsured, or treated or untreated cohorts.</p><p>To see why this might be the case, the authors then performed a ‘<em>sequential weighting procedure’</em>to essentially simulate what might be the case if these patients had equivalent tumor biology, access to care and treatment.</p><p>In effect they were able to answer the question: “Suppose that Black and White men and women had similar tumor characteristics, how would their outcomes vary?” If the racial differences in outcomes were due to different biology, we would expect the differences in outcomes to disappear. On the other hand, if the difference were due to access and treatment, then the differences would persist.</p><h4>In fact, the authors found that access to care (and to a lesser extent treatment) explained the excess risk of death in Blacks far more than tumor biology. Upon balancing the data by characteristics of the individual tumors, the excess risk of death in Black men and women was reduced to 16%. By balancing it by the treatment specific patients received, the number was reduced to 10%. And finally, by balancing by access-related variables, there was discovered to be no difference in mortality rates between white and black patients.</h4><blockquote>Taken together these findings imply that the worse mortality of black patients could be dictated by external factors — more specifically, treatment and access to care.</blockquote><p>This would mean addressing the reality that differences in cancer survival for minorities usually stem <a href="https://www.ncbi.nlm.nih.gov/pubmed/24863392">from income, insurance, and access to care</a> — not biological differences.</p><p>Healthcare is not — nor will it ever be — a one-size-fits-all industry. But as long as we recognize it for what it is, which is a system that needs to consciously and consistently be repaired and monitored, we are taking the first step towards solving this issue of equity.</p><p>The good news is: we now know how.</p><p><a href="https://medium.com/u/98a896759b55"><em>Andrew Cataldo</em></a><em> is a Spring 2019 Urology Writing Fellow.</em></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=69d9da3506c2" width="1" height="1" alt=""><hr><p><a href="https://medium.com/pro-re-nata/can-equal-access-overcome-race-based-differences-in-survival-for-cancer-patients-69d9da3506c2">Can equal access overcome race‐based differences in survival for cancer patients?</a> was originally published in <a href="https://medium.com/pro-re-nata">pro re nata</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[How picking the right hospital can help cancer patients live longer]]></title>
            <link>https://medium.com/pro-re-nata/how-picking-the-right-hospital-can-help-cancer-patients-live-longer-80bdb7d19485?source=rss-dfa0c514e8a6------2</link>
            <guid isPermaLink="false">https://medium.com/p/80bdb7d19485</guid>
            <category><![CDATA[cancer]]></category>
            <category><![CDATA[life]]></category>
            <category><![CDATA[wisdom]]></category>
            <category><![CDATA[ideas]]></category>
            <category><![CDATA[health]]></category>
            <dc:creator><![CDATA[Quoc-Dien Trinh]]></dc:creator>
            <pubDate>Fri, 09 Feb 2018 15:50:40 GMT</pubDate>
            <atom:updated>2018-02-09T15:50:40.150Z</atom:updated>
            <content:encoded><![CDATA[<p>Small changes can often lead to big gains.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*y8Zs_mNpAC3vk1bw2FBsjg.jpeg" /><figcaption>Photo by Unsplash</figcaption></figure><p><em>Story by: Sarah E Dunlap and Alexander P Cole</em></p><p>Often — as any physician who cares for cancer patients would attest — anxious patients ask: what would improve their chances of living longer?</p><p>This is the question that intrigued our research group. Although general media is quick to place a lot of focus on the latest buzz in cancer therapy — from <a href="https://www.cancer.gov/about-cancer/treatment/research/car-t-cells">CAR-T cell therapy</a> to the <a href="https://www.wsj.com/articles/cancer-drug-price-rises-1400-with-no-generic-to-challenge-it-1514203201">most expensive drug available </a>— research shows the answer is usually simple. And, several times better.</p><blockquote>It is well-known that to research, develop, and bring a new cancer drug to market may cost over <a href="https://www.scientificamerican.com/article/cost-to-develop-new-pharmaceutical-drug-now-exceeds-2-5b/">a billion dollars</a>, and can take upwards of seven years. For patients, usually, this translates to very high costs leading to <a href="https://www.reuters.com/article/us-health-cancer-financing/for-working-age-cancer-survivors-debt-and-bankruptcy-are-common-idUSKBN0UJ24F20160105">debt and bankruptcy</a> in extreme cases. Few would argue against spending money to achieve the one result that nearly all cancer patients want: more time. But what if simply picking the right hospital could also make a difference?</blockquote><p>Our research team investigated this. In a recently published <a href="http://onlinelibrary.wiley.com/doi/10.1002/cncr.31254/full%20%E2%80%A6">study</a>, we sought to quantify how much longer men and women might survive if they chose to have surgery at “high-volume hospitals”, meaning hospitals that performed a high number of surgeries in comparison to others.</p><blockquote>Just like elite teams of athletes and musicians improve with hours of practice, hospitals with more experience have better short-term outcomes for patients.</blockquote><p>Patients receiving surgery at these “high-volume” hospitals have fewer complications and recover faster than patients receiving the same surgery at less-experienced hospitals. This is especially true in complex cancer surgeries.</p><p>But at the end of the day, what cancer patients care about is living longer.</p><p>In this study, we looked at a common, <a href="https://www.clinicaladvisor.com/critical-care-medicine/high-risk-operations/article/585833/">high-risk</a> cancer surgery: radical cystectomy for bladder cancer. A 5-plus hour surgery which can cure high-risk bladder cancer requires a high level of surgical skill, as well as quality post-operative care, but also poses risks of <a href="https://www.webmd.com/cancer/bladder-cancer/cystectomy-for-bladder-cancer">significant complications</a>. To understand how much better high-volume centers actually do, we compared average survival for patients who received this operation at high-volume hospitals with those receiving the surgery at low-volume centers. High-volume hospitals, were those in the top tenth of all hospitals in the United States in terms of number of surgeries performed — they performed an average of 33.5 radical cystectomies a year.</p><p>Patients who had surgery at these hospitals lived <em>15-months longer </em>than patients receiving the same procedure at ‘low-volume’ hospitals where an average of only 2.4 radical cystectomies were performed a year. This trend was present even after accounting for differences in patient characteristics and the severity of the cancer diagnosis.</p><p>Though we only analyzed the outcomes for one type of cancer surgery, there is evidence that this same phenomenon is at play with other surgeries, procedures, and outcomes. So, does this mean that you should go to a high-volume hospital for your next major surgery? Most experts would agree that what matters most if finding an institution that is very experienced with your particular surgery. It is <em>always reasonable</em> to ask your surgeon about this or her experience with a specific operation.</p><blockquote>As we listen to ongoing debates about health care spending and impassioned speeches about the high cost of next generation cancer drugs, it is worth remembering that seemingly boring little changes can have a big impact.</blockquote><p>Oftentimes, patients are excited to read the latest news article about high-tech cancer treatments ranging from cancer vaccines to T-cell treatments. This is understandable. Everyone wants access to the latest and greatest new options. But at the end of the day, these results remind us that simple steps like choosing a standard treatment done by an experienced surgical team may be far more efficacious in getting cancer patients the outcome that they most hope for.</p><p>No one would argue that we should give up on the search for the next blockbuster cancer drug. As long as there has been cancer, doctors and patients alike have dreamed of an agent that can target and kill cancer cells, while leaving normal cells unharmed. The greatest minds in medicine are hard at work on this task; with advances in precision medicine techniques, we are closer than ever before to getting there.</p><p>At the same time, it is important to remember that seemingly mundane, system-wide modifications can also improve long-term outcomes. If we are willing to spend upwards of 1.7 million dollars a blockbuster cancer drug which yields nine more months cancer free-as was recently described in an <a href="https://jamanetwork.com/journals/jamaoncology/article-abstract/2656872?redirect=true">editorial in JAMA Oncology</a>, it makes sense to invest in simple system based changes as well.</p><p>While these modifications may not draw headlines or turn heads, they are no less an important tool for improving clinical outcomes for our patients, and can empower them in making informed decisions.</p><p><em>This story was contributed by </em><a href="https://medium.com/u/11bd2ee72d01"><em>Sarah Dunlap</em></a><em> , Spring 2018 Urology Writing Fellow, and </em><a href="https://twitter.com/Putnam_Cole"><em>Alexander P. Cole</em></a><em>, M.D., a urology resident and health services research fellow.</em></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=80bdb7d19485" width="1" height="1" alt=""><hr><p><a href="https://medium.com/pro-re-nata/how-picking-the-right-hospital-can-help-cancer-patients-live-longer-80bdb7d19485">How picking the right hospital can help cancer patients live longer</a> was originally published in <a href="https://medium.com/pro-re-nata">pro re nata</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
    </channel>
</rss>